Symbols / TERN Stock $52.95 Terns Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
TERN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Amy L. Burroughs M.B.A.
Exch · Country NMS · United States
Market Cap 6.12B
Enterprise Value 5.09B
Income -96.21M
Sales —
FCF (ttm) -55.48M
Book/sh 8.96
Cash/sh 8.83
Employees 59
Insider 10d —
IPO Feb 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -34.01
PEG —
P/S —
P/B 5.91
P/C —
EV/EBITDA -46.29
EV/Sales —
Quick Ratio 62.09
Current Ratio 62.41
Debt/Eq 0.09
LT Debt/Eq —
EPS (ttm) -1.03
EPS next Y -1.56
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -9.91%
ROE -14.23%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 115.52M
Shs Float 115.12M
Insider Own 0.25%
Instit Own 109.69%
Short Float 6.99%
Short Ratio 0.70
Short Interest 8.06M
52W High 53.19
vs 52W High -0.45%
52W Low 2.65
vs 52W Low 1,894.35%
Beta -0.38
Impl. Vol. 0.78%
Rel Volume 1.09
Avg Volume 5.83M
Volume 6.33M
Target (mean) $53.00
Tgt Median $53.00
Tgt Low $53.00
Tgt High $53.00
# Analysts 4
Recom Hold
Prev Close $0.00
Price $52.95
Change —
About

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$53.00
Mean price target
2. Current target
$52.95
Latest analyst target
3. DCF / Fair value
$-8.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$52.95
Low
$53.00
High
$53.00
Mean
$53.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 down Oppenheimer Outperform → Perform —
2026-04-14 main JP Morgan Overweight → Overweight $45
2026-03-31 down Truist Securities Buy → Hold $53
2026-03-30 down Barclays Overweight → Equal-Weight $53
2026-03-26 down Citizens Market Outperform → Market Perform —
2026-03-26 down TD Cowen Buy → Hold $53
2026-03-25 down HC Wainwright & Co. Buy → Neutral $53
2025-12-11 main Citizens Market Outperform → Market Outperform $57
2025-12-09 main Truist Securities Buy → Buy $56
2025-12-09 main Oppenheimer Outperform → Outperform $58
2025-12-09 main BMO Capital Outperform → Outperform $54
2025-12-09 main Barclays Overweight → Overweight $56
2025-12-09 main Mizuho Outperform → Outperform $54
2025-12-09 main HC Wainwright & Co. Buy → Buy $60
2025-11-26 main Citizens Market Outperform → Market Outperform $35
2025-11-25 main Barclays Overweight → Overweight $36
2025-11-19 main Truist Securities Buy → Buy $35
2025-11-18 main BMO Capital Outperform → Outperform $30
2025-11-13 main Mizuho Outperform → Outperform $33
2025-11-11 main Barclays Overweight → Overweight $28
News
RSS: Latest TERN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 KURIAKOSE EMIL T. Officer — 942 $52.75 $49,693
2026-03-16 BURROUGHS AMY LOUISE Chief Executive Officer — 14,583 $46.57 $681,108
2026-03-16 BURROUGHS AMY LOUISE Chief Executive Officer — 14,583 $4.64 $67,665
2026-02-17 BURROUGHS AMY LOUISE Chief Executive Officer — 14,583 $38.07 $571,579
2026-02-17 BURROUGHS AMY LOUISE Chief Executive Officer — 14,583 $4.64 $67,665
2026-01-15 BURROUGHS AMY LOUISE Chief Executive Officer — 68,749 $37.02 $2,548,603
2026-01-15 BURROUGHS AMY LOUISE Chief Executive Officer — 68,749 $4.64 $318,995
2026-01-14 GENGOS ANDREW Chief Financial Officer — 68,750 $0.00 $0
2026-01-14 BURROUGHS AMY LOUISE Chief Executive Officer — 150,000 $0.00 $0
2026-01-14 KURIAKOSE EMIL T. Officer — 56,250 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
110.12
+8.10%
101.87
-0.67%
102.56
+65.34%
62.03
Research And Development
77.89
+11.09%
70.11
+10.42%
63.50
+60.28%
39.62
Selling General And Administration
32.23
+1.50%
31.76
-18.69%
39.06
+74.29%
22.41
General And Administrative Expense
32.23
+1.50%
31.76
-18.69%
39.06
+74.29%
22.41
Other Gand A
32.23
+1.50%
31.76
-18.69%
39.06
+74.29%
22.41
Total Expenses
110.12
+8.10%
101.87
-0.67%
102.56
+65.34%
62.03
Operating Income
-110.12
-8.10%
-101.87
+0.67%
-102.56
-65.34%
-62.03
Total Operating Income As Reported
-110.12
-8.10%
-101.87
+0.67%
-102.56
-65.34%
-62.03
EBITDA
-109.62
-8.56%
-100.97
+0.69%
-101.68
-66.69%
-61.00
Normalized EBITDA
-109.62
-8.56%
-100.97
+0.69%
-101.68
-66.69%
-61.00
Reconciled Depreciation
0.50
-44.08%
0.90
+1.70%
0.88
-14.63%
1.03
EBIT
-110.12
-8.10%
-101.87
+0.67%
-102.56
-65.34%
-62.03
Net Income
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Pretax Income
-95.63
-7.94%
-88.59
+1.53%
-89.97
-49.98%
-59.99
Net Non Operating Interest Income Expense
14.59
+9.80%
13.29
+3.01%
12.90
+511.42%
2.11
Net Interest Income
14.59
+9.80%
13.29
+3.01%
12.90
+511.42%
2.11
Interest Income Non Operating
14.59
+9.80%
13.29
+3.01%
12.90
+511.42%
2.11
Interest Income
14.59
+9.80%
13.29
+3.01%
12.90
+511.42%
2.11
Other Income Expense
-0.09
-745.45%
-0.01
+96.50%
-0.31
-361.76%
-0.07
Other Non Operating Income Expenses
-0.09
-745.45%
-0.01
+96.50%
-0.31
-361.76%
-0.07
Tax Provision
0.58
+123.46%
0.26
+8.79%
0.24
-33.24%
0.36
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Net Income From Continuing Operation Net Minority Interest
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Net Income From Continuing And Discontinued Operation
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Net Income Continuous Operations
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Minority Interests
—
—
—
—
Normalized Income
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Net Income Common Stockholders
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-1.12
+11.81%
-1.27
+23.95%
-1.67
Basic EPS
—
-1.12
+11.81%
-1.27
+23.95%
-1.67
Basic Average Shares
—
79.51
+11.57%
71.26
+97.76%
36.03
Diluted Average Shares
—
79.51
+11.57%
71.26
+97.76%
36.03
Diluted NI Availto Com Stockholders
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,025.08
+181.67%
363.93
+35.53%
268.52
-6.45%
287.03
Current Assets
1,024.19
+182.84%
362.11
+35.40%
267.43
-6.23%
285.19
Cash Cash Equivalents And Short Term Investments
1,018.98
+184.50%
358.16
+35.96%
263.44
-6.95%
283.11
Cash And Cash Equivalents
524.75
+225.04%
161.44
+101.99%
79.93
-44.20%
143.24
Cash Equivalents
500.79
+239.37%
147.57
+336.74%
33.79
+46.72%
23.03
Cash Financial
23.96
+72.70%
13.87
-69.93%
46.14
-61.62%
120.21
Other Short Term Investments
494.24
+151.23%
196.72
+7.20%
183.51
+31.19%
139.88
Receivables
—
—
—
—
Prepaid Assets
—
—
—
—
Current Deferred Assets
—
—
—
—
Other Current Assets
5.21
+32.12%
3.94
-1.18%
3.99
+92.76%
2.07
Total Non Current Assets
0.88
-51.43%
1.82
+67.74%
1.08
-41.06%
1.84
Net PPE
0.88
-39.86%
1.47
+42.86%
1.03
-42.96%
1.80
Gross PPE
1.57
-53.42%
3.36
+27.45%
2.64
-17.72%
3.21
Accumulated Depreciation
-0.68
+63.95%
-1.89
-17.59%
-1.61
-14.76%
-1.40
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.84
-32.93%
1.25
+138.62%
0.52
-50.05%
1.05
Machinery Furniture Equipment
0.55
-11.18%
0.62
+0.98%
0.61
-4.98%
0.64
Other Properties
—
0.75
-2.99%
0.77
+1.58%
0.76
Leases
0.18
-75.87%
0.75
+2.18%
0.73
-3.17%
0.76
Other Non Current Assets
—
0.35
+525.00%
0.06
+51.35%
0.04
Total Liabilities Net Minority Interest
18.55
+2.74%
18.06
+37.33%
13.15
+30.42%
10.08
Current Liabilities
16.41
+4.86%
15.65
+31.03%
11.94
+41.05%
8.47
Payables And Accrued Expenses
8.57
+25.03%
6.86
+27.42%
5.38
+42.37%
3.78
Payables
1.72
-19.88%
2.15
-14.59%
2.52
+52.89%
1.65
Accounts Payable
1.72
-19.88%
2.15
-14.59%
2.52
+52.89%
1.65
Current Accrued Expenses
6.85
+45.53%
4.71
+64.29%
2.87
+34.25%
2.13
Pensionand Other Post Retirement Benefit Plans Current
6.92
-12.58%
7.91
+39.22%
5.68
+47.88%
3.84
Current Debt And Capital Lease Obligation
0.47
+10.75%
0.43
-29.02%
0.60
-8.77%
0.66
Current Capital Lease Obligation
0.47
+10.75%
0.43
-29.02%
0.60
-8.77%
0.66
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
0.45
-1.32%
0.46
+63.67%
0.28
+50.27%
0.18
Total Non Current Liabilities Net Minority Interest
2.14
-11.04%
2.41
+99.75%
1.21
-25.33%
1.61
Long Term Debt And Capital Lease Obligation
0.45
-51.58%
0.92
0.00
-100.00%
0.54
Long Term Capital Lease Obligation
0.45
-51.58%
0.92
0.00
-100.00%
0.54
Tradeand Other Payables Non Current
1.70
+13.96%
1.49
+23.55%
1.21
+12.61%
1.07
Non Current Deferred Liabilities
—
—
—
0.00
Stockholders Equity
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Common Stock Equity
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Capital Stock
0.01
+22.22%
0.01
+50.00%
0.01
+20.00%
0.01
Common Stock
0.01
+22.22%
0.01
+50.00%
0.01
+20.00%
0.01
Preferred Stock
—
—
—
—
Share Issued
112.32
+28.92%
87.13
+34.92%
64.58
+20.20%
53.72
Ordinary Shares Number
112.32
+28.92%
87.13
+34.92%
64.58
+20.20%
53.72
Additional Paid In Capital
1,523.94
+98.53%
767.62
+30.55%
588.01
+13.04%
520.18
Retained Earnings
-517.69
-22.83%
-421.48
-26.71%
-332.63
-37.21%
-242.42
Gains Losses Not Affecting Retained Earnings
0.26
+193.19%
-0.28
-1368.42%
-0.02
+97.69%
-0.82
Other Equity Adjustments
0.26
+193.19%
-0.28
-1368.42%
-0.02
+97.69%
-0.82
Total Equity Gross Minority Interest
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Total Capitalization
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Working Capital
1,007.78
+190.88%
346.46
+35.61%
255.49
-7.67%
276.72
Invested Capital
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Total Debt
0.92
-31.77%
1.35
+123.38%
0.60
-49.96%
1.21
Capital Lease Obligations
0.92
-31.77%
1.35
+123.38%
0.60
-49.96%
1.21
Net Tangible Assets
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Tangible Book Value
1,006.52
+191.01%
345.87
+35.44%
255.37
-7.79%
276.94
Notes Receivable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-82.18
-17.37%
-70.02
-3.90%
-67.39
-37.23%
-49.11
Cash Flow From Continuing Operating Activities
-82.18
-17.37%
-70.02
-3.90%
-67.39
-37.23%
-49.11
Net Income From Continuing Operations
-96.21
-8.28%
-88.85
+1.50%
-90.21
-49.49%
-60.34
Depreciation Amortization Depletion
0.50
-44.08%
0.90
+1.70%
0.88
-14.63%
1.03
Depreciation
0.50
-44.08%
0.90
+1.70%
0.88
-14.63%
1.03
Depreciation And Amortization
0.50
-44.08%
0.90
+1.70%
0.88
-14.63%
1.03
Stock Based Compensation
13.40
-14.26%
15.63
-38.80%
25.54
+137.15%
10.77
Deferred Tax
0.51
+2121.74%
0.02
-83.69%
0.14
-64.03%
0.39
Deferred Income Tax
0.51
+2121.74%
0.02
-83.69%
0.14
-64.03%
0.39
Change In Working Capital
-0.32
-107.33%
4.38
+197.02%
1.48
+242.24%
-1.04
Change In Prepaid Assets
-1.18
-2612.77%
0.05
+102.45%
-1.92
-71.36%
-1.12
Change In Payables And Accrued Expense
1.29
-73.61%
4.89
+20.36%
4.06
+485.30%
0.69
Change In Accrued Expense
1.80
-65.72%
5.26
+80.43%
2.91
+105.72%
1.42
Change In Payable
-0.51
-39.51%
-0.37
-131.94%
1.15
+259.14%
-0.72
Change In Account Payable
-0.51
-39.51%
-0.37
-131.94%
1.15
+259.14%
-0.72
Change In Other Working Capital
—
—
—
-0.61
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
-0.43
+22.52%
-0.56
+16.67%
-0.67
-9.18%
-0.61
Investing Cash Flow
-298.04
-2301.64%
-12.41
+67.33%
-37.99
-70.56%
-22.27
Cash Flow From Continuing Investing Activities
-298.04
-2301.64%
-12.41
+67.33%
-37.99
-70.56%
-22.27
Net PPE Purchase And Sale
0.00
+100.00%
-0.04
+19.23%
-0.05
+81.09%
-0.28
Purchase Of PPE
0.00
+100.00%
-0.04
+19.23%
-0.05
+81.09%
-0.28
Capital Expenditure
—
-0.04
+19.23%
-0.05
+81.09%
-0.28
Net Investment Purchase And Sale
-298.04
-2309.79%
-12.37
+67.40%
-37.94
-72.46%
-22.00
Purchase Of Investment
-405.04
-138.34%
-169.94
+38.38%
-275.78
-97.37%
-139.73
Sale Of Investment
107.00
-32.10%
157.57
-33.75%
237.85
+102.02%
117.73
Financing Cash Flow
743.51
+353.37%
164.00
+290.92%
41.95
-74.89%
167.09
Cash Flow From Continuing Financing Activities
743.51
+353.37%
164.00
+290.92%
41.95
-74.89%
167.09
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
706.39
+335.20%
162.31
+290.07%
41.61
-75.12%
167.25
Proceeds From Stock Option Exercised
37.36
+1703.86%
2.07
+202.78%
0.68
+181.48%
0.24
Net Other Financing Charges
-0.23
+39.43%
-0.39
-12.79%
-0.34
+14.21%
-0.40
Changes In Cash
363.29
+345.38%
81.57
+228.60%
-63.43
-166.27%
95.71
Effect Of Exchange Rate Changes
0.02
+128.57%
-0.06
-147.86%
0.12
+165.73%
-0.18
Beginning Cash Position
161.44
+101.99%
79.93
-44.20%
143.24
+200.29%
47.70
End Cash Position
524.75
+225.04%
161.44
+101.99%
79.93
-44.20%
143.24
Free Cash Flow
-82.18
-17.30%
-70.06
-3.88%
-67.44
-36.57%
-49.38
Income Tax Paid Supplemental Data
0.22
+263.33%
0.06
+114.29%
0.03
+833.33%
0.00
Amortization Of Securities
-0.06
+97.22%
-2.09
+59.91%
-5.21
-6535.80%
0.08
Change In Interest Payable
1.17
+15.91%
1.01
+450.00%
0.18
—
Common Stock Issuance
706.39
+335.20%
162.31
+290.07%
41.61
-75.12%
167.25
Issuance Of Capital Stock
706.39
+335.20%
162.31
+290.07%
41.61
-75.12%
167.25
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category